According to the research report, the Therapeutic Monoclonal Antibodies Market is projected to display significant growth represented by a CAGR of 18.63% during 2022-2028. The Global Therapeutic Monoclonal Antibodies Market was valued at USD 334.38 Billion in the year 2021 with the Americas region leading the regional market share.
The Therapeutic Monoclonal Antibodies market's demand has surged in the past year due to the increasing incidence of chronic diseases like cancer, autoimmune disorders, infectious diseases, Neurological and cardiovascular diseases.
America is the largest market for Therapeutic Monoclonal Antibodies with the U.S. accounting for a major share of the total Therapeutic Monoclonal Antibodies consumption in the region.
The European region is a lucrative market and is growing at an exponential rate during the forecast period owing to the rising prevalence of chronic diseases due to the large geriatric population as well as the developed healthcare infrastructure of countries like the United Kingdom and Germany.
Asia Pacific region is the fastest growing region owing to the rapid development and entry of major players in the APAC region and is anticipated to register the fastest growth during the forecast period.
Scope of the Report
- The report presents the analysis of Therapeutic Monoclonal Antibodies Market for the forecast period of 2023-2028.
- The report analyses the Therapeutic Monoclonal Antibodies Market by value (USD Billion).
- The report analyses the Therapeutic Monoclonal Antibodies By Source (Humanized, Murine, Chimeric, Human)
- The report analyses the Therapeutic Monoclonal Antibodies Market, By Target (Cell surface antigen, plasma protein or drug, Other Targets, infectious organism)
- The report analyses the Therapeutic Monoclonal Antibodies Market by Indication (Cancer, Infectious Disease, Autoimmune Disorders, Neurological Disorders, Other Indications).
- The report analyses the Therapeutic Monoclonal Antibodies Market by Route of Administration (Intravenous, Subcutaneous, Other ROA).
- The Global Therapeutic Monoclonal Antibodies Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
- The Global Therapeutic Monoclonal Antibodies Market has been analysed By Country (United States, Canada, Germany, U.K, France, Spain, Italy, China, Japan, India).
- The key insights of the report have been presented through the leading company shares. Also, the attractiveness of the market has been presented by region, by Source, by Target, by Indication, by route of administration.
- Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The report tracks competitive developments, strategies, and recent developments. The companies analysed in the report include Eli Lily and Co., GSK plc, Roche, AstraZenca plc, Bayer, Amgen, Johnson & Johnson, Pfizer, Novartis, Merck & Co.
Key Target Audience:
- Biotechnology Companies
- Pharmaceutical Companies
- Research and Development (R&D) Organizations
- Government Bodies & Regulating Authorities
- Investment Banks and Equity Firms
Table of Contents
1. Introduction
1.1 Therapeutic Monoclonal Antibodies Market Overview
1.2 Scope of Research
2. Executive Summary
2.1 Market Snapshot
2.2 Regional Insights
2.3 Market Ecosystem Factors
3. Research Methodology
3.1 Data Collection Process
3.2 Market Trajectory Estimation
3.3 Market Size Calculation-Top-to-Bottom
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Trends
4.5 Analyst Recommendations
4.6 Impact Analysis
5. Value Chain Analysis
6. COVID-19 Impact Assessment
6.1 Degree of Impact of COVID-19 on Therapeutic Monoclonal Antibodies Market
6.2 Region-Wise Quarterly Coved Impact Analysis (2020)
7. Porter's Five Forces Analysis
8. Macro Economic Indicator Outlook
8.1 GDP per capita growth (annual %)
8.2 Global Medical Spending
8.3 Current Healthcare Expenditure
8.4 Pharmaceutical Spending/capita
9. Competitive Positioning
9.1 Companies’ Product Positioning
9.2 Market Position Matrix
9.3 Market Share Analysis of Therapeutic Monoclonal Antibodies Market
9.4 Company profiles
9.4.1 Eli-Lily & Co
9.4.2 GSK plc.
9.4.3 Bayer AG
9.4.4 Johnson & Johnson
9.4.5 Amgen
9.4.6 Astra Zeneca plc.
9.4.7 Novartis
9.4.8 Merck & Co., Inc.
9.4.9 Pfizer Inc.
9.4.10 Roche Holding AG
10. Global Therapeutic Monoclonal Antibodies Market
10.1 Impact Analysis of Macro Economic Factors on Therapeutic Monoclonal Antibodies Market
10.2 Market Size and CAGR
10.3 Global Therapeutic Monoclonal Antibodies Market: Market Value Assessment
10.4 Market Summary
11. Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Source
11.1 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, By Source: Snapshot
11.2 Humanized
11.3 Murine
11.4 Chimeric
11.5 Human
12. Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Target
12.1 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, By Target: Snapshot
12.2 Cell surface antigen
12.3 Plasma protein or drug
12.4 Infectious organism
12.5 Other Targets
13. Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Indication
13.1 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, By Indication: Snapshot
13.2 Cancer
13.3 Infectious Disease
13.4 Autoimmune Disorders
13.5 Neurological Disorders
13.6 Other Indications
14. Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Route of Administration
14.1 Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, By Indication: Snapshot
14.2 Intravenous
14.3 Subcutaneous
14.4 Other ROA
15. Global Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis, 2018-2028, By Region
15.1 Regional Coverage of the Study
16. Americas Therapeutic Monoclonal Antibodies Market Trends and Forecast Analysis, 2018-2028, USD Billion & CAGR
16.1 Macro Economic Factor Impact Index
16.2 Impact analysis of market dynamics on Therapeutic Monoclonal Antibodies Market
16.3 Americas Therapeutic Monoclonal Antibodies Market: Snapshot
16.4 Americas Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2028(USD Billion)
16.5 Americas Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis: Segmentation
16.5.1 By Source
16.5.2 By Target
16.5.3 By Indication
16.5.4 By Route of Administration
16.5.5 By Country
16.5.5.1 United States
16.5.5.2 Canada
16.5.5.3 Brazil
17. Europe Therapeutic Monoclonal Antibodies Market Trends and Forecast Analysis, 2018-2028, USD Billion & CAGR
17.1 Macro Economic Factor Impact Index
17.2 Impact analysis of market dynamics on Therapeutic Monoclonal Antibodies Market
17.3 Europe Therapeutic Monoclonal Antibodies Market: Snapshot
17.4 Europe Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2028(USD Billion)
17.5 Europe Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis: Segmentation
17.5.1 By Source
17.5.2 By Target
17.5.3 By Indication
17.5.4 By Route of Administration
17.5.5 By Country
17.5.5.1 Germany
17.5.5.2 United Kingdom
17.5.5.3 France
17.5.5.4 Italy
17.5.5.5 Spain
17.5.5.6 Rest of Europe
18. Asia Pacific Therapeutic Monoclonal Antibodies Market Trends and Forecast Analysis, 2018-2028, USD Billion & CAGR
18.1 Macro Economic Factor Impact Index
18.2 Impact analysis of market dynamics on Therapeutic Monoclonal Antibodies Market
18.3 Asia Pacific Therapeutic Monoclonal Antibodies Market: Snapshot
18.4 Asia Pacific Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2028(USD Billion)
18.5 Asia Pacific Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis: Segmentation
18.5.1 By Source
18.5.2 By Target
18.5.3 By Indication
18.5.4 By Route of Administration
18.5.5 By Country
18.5.5.1 China
18.5.5.2 Japan
18.5.5.3 India
18.5.5.4 Rest of Asia Pacific
19. Middle East & Africa Therapeutic Monoclonal Antibodies Market Trends and Forecast Analysis, 2018-2028, USD Billion & CAGR
19.1 Macro Economic Factor Impact Index
19.2 Impact analysis of market dynamics on Therapeutic Monoclonal Antibodies Market
19.3 Middle East & Africa Therapeutic Monoclonal Antibodies Market: Snapshot
19.4 Middle East Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2028(USD Billion)
19.5 Middle East & Africa Therapeutic Monoclonal Antibodies Market Trend and Forecast Analysis: Segmentation
19.5.1 By Source
19.5.2 By Target
19.5.3 By Indication
19.5.4 By Route of Administration
List of Figures
Figure 1: Therapeutic Monoclonal Antibodies Market for next 7 years (in USD Millions)
Figure 2: Therapeutic Monoclonal Antibodies Market Size, By Route of Administration, 2018 & 2028 (USD Million)
Figure 3: Therapeutic Monoclonal Antibodies Market Size by Target, 2021 (%)
Figure 4: Market Share of Prominent Companies of Therapeutic Monoclonal Antibodies, 2021 (%)
Figure 5: Eli Lilly and Company Revenues, 2019-2021 (USD Million)
Figure 6: Eli Lilly and Company Revenues Revenue, By Business Segments, 2021 (%)
Figure 7: Eli Lilly and Company Revenues Revenue, By Business Segments, 2021 (%)
Figure 8: GSK plc. Revenues, 2019-2021 (USD Million)
Figure 9: GSK plc. Revenue, By Business Segments, 2021 (%)
Figure 10: GSK plc. Revenue, By Business Segments, 2021 (%)
Figure 11: Bayer AG. Revenues, 2019-2021 (USD Million)
Figure 12: Bayer AG. Revenue, By Business Segments, 2021 (%)
Figure 13: Bayer AG. Revenue, By Business Segments, 2021 (%)
Figure 14: Johnson & Johnson Revenues, 2019-2021 (USD Million)
Figure 15: J&J Revenue, By Business Segments, 2021 (%)
Figure 16: J&J Revenue, By Business Segments, 2021 (%)
Figure 17: Amgen Pharmaceuticals Revenues, 2019-2021 (USD Million)
Figure 18: Amgen Revenue, By Business Segments, 2021 (%)
Figure 19: Amgen Revenue, By Business Segments, 2020 (%)
Figure 20: Astra Zeneca Revenues, 2019-2021 (USD Million)
Figure 21: Astra Zeneca Revenue, Product Sales by Disease Area, 2021 (%)
Figure 22: Astra Zeneca Revenue, By Geographical Segments, 2021 (%)
Figure 23: Novartis Revenues, 2019-2021 (USD million)
Figure 24: Novartis Revenue, By Business Segments, 2021 (%)
Figure 25: Novartis Revenue, By Business Segments, 2021 (%)
Figure 26: Merck & Co., Inc. Revenues, 2019-2021 (USD Million)
Figure 27: Merck & Co., Inc. Revenue, By Geographic segment, 2021 (%)
Figure 28: Merck & Co., Inc. Revenue, By Business Segments, 2021 (%)
Figure 29: Pfizer Inc. Revenues, 2019-2021 (USD Million)
Figure 30: Pfizer Inc. Revenue, By Business Segments- By Products, 2021 (%)
Figure 31: Pfizer Inc. Revenue, By Business Segments, 2021 (%)
Figure 32: Roche Revenues, 2019-2021 (USD Million)
Figure 33: Roche Revenue, By Business Segments- By Products, 2021 (%)
Figure 34: Roche Revenue, By Business Segments, 2021 (%)
Figure 35a: At a CAGR of 18.63% during 2023-2028, the global market value is expected to reach USD 1076.64 billion in 2028
Figure 35b: Value sales of Therapeutic Monoclonal Antibodies is expected to sustain a staggering sale of 1076.64 billion in 2028
Figure 36: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Region (2022,2028)
Figure 37: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Region (2023-2028)
Figure 38: Global Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2021(USD Billion)
Figure 39: Global Therapeutic Monoclonal Antibodies Market Size, By Value, 2022-2028 (USD Billion)
Figure 40: Global Therapeutic Monoclonal Antibodies Market Share, By Indication, 2021 (%)
Figure 41: Global Therapeutic Monoclonal Antibodies Market CAGR, By Source, By Value, 2018-2021, 2023-2028 (%)
Figure 42: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Source (2022,2028)
Figure 43: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Source (2023-2028)
Figure 44: Global Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2018-2021 (USD Billion)
Figure 45: Global Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2022-2028 (USD Billion)
Figure 46: Global Humanized Therapeutic Monoclonal Antibodies Absolute Opportunity, 2018-2028 (USD Billion)
Figure 47: Global Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2018-2021 (USD Billion)
Figure 48: Global Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2022-2028 (USD Billion)
Figure 49: Global Murine Therapeutic Monoclonal Antibodies Absolute Opportunity, 2018-2028 (USD Billion)
Figure 50: Global Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2018-2021 (USD Billion)
Figure 51: Global Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2022-2028 (USD Billion)
Figure 52: Global Chimeric, Therapeutic Monoclonal Antibodies Absolute Opportunity, 2018-2028 (USD Billion)
Figure 53: Global Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2018-2021 (USD Billion)
Figure 54: Global Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2022-2028 (USD Billion)
Figure 55: Global Human, Therapeutic Monoclonal Antibodies Absolute Opportunity, 2018-2028 (USD Billion)
Figure 56: Global Therapeutic Monoclonal Antibodies Market CAGR, By Target, By Value, 2018-2021, 2023-2028 (%)
Figure 57: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Target (2022,2028)
Figure 58: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Target (2023-2028)
Figure 59: Global Therapeutic Monoclonal Antibodies Market Size, By Cell surface antigen, By Value, 2018-2021 (USD Million)
Figure 60: Global Therapeutic Monoclonal Antibodies Market Size, By Cell surface antigen, By Value, 2022-2028 (USD Million)
Figure 61: Global Therapeutic Monoclonal Antibodies Market, By Cell surface antigen, Absolute Opportunity, By Value, 2018-2028 (USD Million)
Figure 62: Global Therapeutic Monoclonal Antibodies Market Size, By Plasma protein or drug, By Value, 2018-2021 (USD Billion)
Figure 63: Global Therapeutic Monoclonal Antibodies Market Size, Plasma protein or drug, By Value, 2022-2028 (USD Billion)
Figure 64: Global Therapeutic Monoclonal Antibodies Market, By Plasma protein or drug, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 65: Global Therapeutic Monoclonal Antibodies Market Size, By Infectious organism, By Value, 2018-2021 (USD Billion)
Figure 66: Global Therapeutic Monoclonal Antibodies Market Size, By Infectious organism, By Value, 2022-2028 (USD Billion)
Figure 67: Global Therapeutic Monoclonal Antibodies Market, By Infectious organism, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 68: Global Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2018-2021 (USD Billion)
Figure 69: Global Therapeutic Monoclonal Antibodies Market Size, By Other Targets, By Value, 2022-2028 (USD Billion)
Figure 70: Global Therapeutic Monoclonal Antibodies Market, By Other Targets, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 71: Global Therapeutic Monoclonal Antibodies Market CAGR, By Indication, By Value, 2018-2021, 2023-2028 (%)
Figure 72: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Indication (2022,2028)
Figure 73: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Indication (2023-2028)
Figure 74: Global Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2018-2021 (USD Million)
Figure 75: Global Therapeutic Monoclonal Antibodies Market Size, By Cancer, By Value, 2022-2028 (USD Million)
Figure 76: Global Therapeutic Monoclonal Antibodies Market, By Cancer, Absolute Opportunity, By Value, 2018-2028 (USD Million)
Figure 77: Global Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2018-2021 (USD Billion)
Figure 78: Global Therapeutic Monoclonal Antibodies Market Size, By Infectious Disease, By Value, 2022-2028 (USD Billion)
Figure 79: Global Therapeutic Monoclonal Antibodies Market, By Infectious Disease, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 80: Global Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2018-2021 (USD Billion)
Figure 81: Global Therapeutic Monoclonal Antibodies Market Size, By Autoimmune Disorders, By Value, 2022-2028 (USD Billion)
Figure 82: Global Therapeutic Monoclonal Antibodies Market, By Autoimmune Disorders, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 83: Global Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2018-2021 (USD Billion)
Figure 84: Global Therapeutic Monoclonal Antibodies Market Size, By Neurological Disorders, By Value, 2022-2028 (USD Billion)
Figure 85: Global Therapeutic Monoclonal Antibodies Market, By Neurological Disorders, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 86: Global Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2018-2021 (USD Billion)
Figure 87: Global Therapeutic Monoclonal Antibodies Market Size, By Other Indications, By Value, 2022-2028 (USD Billion)
Figure 88: Global Therapeutic Monoclonal Antibodies Market, By Other Indications, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 89: Global Therapeutic Monoclonal Antibodies Market CAGR, By Route of Administration, By Value, 2018-2021, 2023-2028 (%)
Figure 90: Basis Point Analysis of Global Therapeutic Monoclonal Antibodies Market, By Route of Administration (2022,2028)
Figure 91: Market Opportunity Analysis of Global Therapeutic Monoclonal Antibodies Market, By Route of Administration (2023-2028)
Figure 92: Global Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2018-2021 (USD Million)
Figure 93: Global Therapeutic Monoclonal Antibodies Market Size, By Intravenous, By Value, 2022-2028 (USD Million)
Figure 94: Global Therapeutic Monoclonal Antibodies Market, By Intravenous, Absolute Opportunity, By Value, 2018-2028 (USD Million)
Figure 95: Global Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2018-2021 (USD Billion)
Figure 96: Global Therapeutic Monoclonal Antibodies Market Size, By Subcutaneous, By Value, 2022-2028 (USD Billion)
Figure 97: Global Therapeutic Monoclonal Antibodies Market, By Subcutaneous, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 98: Global Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2018-2021 (USD Billion)
Figure 99: Global Therapeutic Monoclonal Antibodies Market Size, By Other ROA, By Value, 2022-2028 (USD Billion)
Figure 100: Global Therapeutic Monoclonal Antibodies Market, By Other ROA, Absolute Opportunity, By Value2018-2028 (USD Billion)
Figure 101: Market Value of the Americas is expected to grow from USD 88.15 Bn to USD 467.69 Billion in 2028
Figure 102: Americas Therapeutic Monoclonal Antibodies Market is expected to foresee an absolute opportunity of 379.54 during 2018-2028
Figure 103: Market Value by Source
Figure 104: Market Value by Target
Figure 105: Top 2 Countries of Therapeutic Monoclonal Antibodies Market in Americas
Figure 106: Basis Point Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Country (2022,2028)
Figure 107: Market Opportunity Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Country (2023-2028)
Figure 108: Americas Therapeutic Monoclonal Antibodies Market Size, By Value, 2018-2021(USD Billion)
Figure 109: Americas Therapeutic Monoclonal Antibodies Market Size, By Value, 2022-2028 (USD Billion)
Figure 110: Americas Therapeutic Monoclonal Antibodies Market Share, By Source, 2021 (%)
Figure 111: Americas Therapeutic Monoclonal Antibodies Market CAGR, By Source, By Value, 2018-2021, 2023-2028 (%)
Figure 112: Basis Point Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Source (2022,2028)
Figure 113: Market Opportunity Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Source (2023-2028)
Figure 114: Americas Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2018-2021 (USD Billion)
Figure 115: Americas Therapeutic Monoclonal Antibodies Market Size, By Humanized, By Value, 2022-2028 (USD Billion)
Figure 116: Americas Humanized Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 117: Americas Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2018-2021 (USD Billion)
Figure 118: Americas Therapeutic Monoclonal Antibodies Market Size, By Murine, By Value, 2022-2028 (USD Billion)
Figure 119: Americas Murine Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 120: Americas Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2018-2021 (USD Billion)
Figure 121: Americas Therapeutic Monoclonal Antibodies Market Size, By Chimeric, By Value, 2022-2028 (USD Billion)
Figure 122: Americas Chimeric Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 123: Americas Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2018-2021 (USD Billion)
Figure 124: Americas Therapeutic Monoclonal Antibodies Market Size, By Human, By Value, 2022-2028 (USD Billion)
Figure 125: Americas Human Therapeutic Monoclonal Antibodies Footprint in Global Market, 2021 (% of Global Market)
Figure 126: Americas Therapeutic Monoclonal Antibodies Market CAGR, By Target, By Value, 2018-2021, 2023-2028 (%)
Figure 127: Basis Point Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Target (2022,2028)
Figure 128: Market Opportunity Analysis of Americas Therapeutic Monoclonal Antibodies Market, By Target (2023-2028)
Figure 129: Americas Therapeutic Monoclonal Antibodies Market Size, By Cell surface antigen, By Value, 2018-2021 (USD Million)
Figure 130: Americas Therapeutic Monoclonal Antibodies Market Size, By Cell surface antigen, By Value, 2022-2028 (USD Million)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 340 |
| Published | November 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 390.8 Billion |
| Forecasted Market Value ( USD | $ 1076.4 Billion |
| Compound Annual Growth Rate | 18.6% |
| Regions Covered | Global |
